CHGCY 23.53 Chugai Pharmaceutical Co., Ltd.
| Range: | 14.1-25.99 | Vol Avg: | 80646 | Last Div: | 0.27 | Changes: | 0.84 |
| Beta: | 0.53 | Cap: | 79.51B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Fri Aug 03 2012 | Empoloyees: | 7604 | ||
| CUSIP: | 171269103 | CIK: | 0001453934 | ISIN: | US1712691039 | Country: | JP |
| CEO: | Dr. Osamu Okuda | Website: | https://www.chugai-pharm.co.jp | ||||
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow